Assessment of adherence to antithrombotic therapy in patients with atrial fibrillation during the COVID-19 pandemic

Tulepbergenov G. Almukhanova A. Ospanova D. Zhangelova S. Musayev A. Akhmetova G. Mambetova I. Кapsultanova D.
July 2023 Malaysian Medical Association

Medical Journal of Malaysia
2023 #78 Issue 4 445 - 448 pp.

Introduction: Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how coronavirus infection (CVI) influences atrial fibrillation (AF), the most prevalent arrhythmia in clinical practice. Materials and Methods: We examined 621 patients with AF using the Morisky-Green scale (MMAS-4) criteria to assess adherence to antithrombotic therapy. They received inpatient treatment during the COVID-19 pandemic. Results: A total of 118 patients out of 621 underwent CVI. Most patients had mild (33.9%) and moderate (49.15%) CVI. We managed to confirm the data of studies by foreign authors, according to which treatment with anticoagulants for at least 1 month reduces the severity of coronavirus infection, as well as protects against thrombotic complications. Conclusion: It is necessary to improve the management of AF, especially if someone was infected with COVID-19. The susceptibility to AF is increased in the acute phase of COVID-19 infection. Personal electrocardiogram devices as well as remote monitoring (teleconsultations) could optimise the care of such patients.

antithrombotic therapy , Atrial fibrillation , COVID-19 , Morisky-Green scale

Text of the article Перейти на текст статьи

Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
Kazakh-Russian Medical University, Almaty, Kazakhstan
Al-Farabi Kazakh National University, Almaty, Kazakhstan

Asfendiyarov Kazakh National Medical University
Kazakh-Russian Medical University
Al-Farabi Kazakh National University

10 лет помогаем публиковать статьи Международный издатель

Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026